Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | WEE1 | P30291 | 1/20 | 0.32 |
| ▸ | TBXAS1 | P24557 | 4/20 | 0.32 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | FDPS | P14324 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | MMP14 | P50281 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28410390 | 0.82 | ALDH1A1 (0.38) | CYP19A1ALDH1A1EGLN3MAPTWEE1 | |
| SCHEMBL9109216 | 0.78 | CYP19A1 (0.37) | CYP19A1ALDH1A1EGLN3MAPTWEE1 | |
| SCHEMBL6735760 | 0.77 | ALDH1A1 (0.43) | CYP19A1ALDH1A1EGLN3MAPTTBXAS1 | |
| SCHEMBL11463256 | 0.77 | EGLN3 (0.45) | ALDH1A1EGLN3MAPTWEE1TBXAS1 | |
| SCHEMBL8761373 | 0.75 | — | — | |
| SCHEMBL11181801 | 0.74 | — | — | |
| SCHEMBL1161357 | 0.74 | — | — | |
| SCHEMBL22117141 | 0.74 | EGLN3 (0.42) | ALDH1A1EGLN3WEE1TBXAS1 | |
| SCHEMBL5217912 | 0.74 | — | — | |
| SCHEMBL8283346 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2433989-B1 | LIGHT-ABSORBING MATERIAL AND PHOTOELECTRIC CONVERSION ELEMENT | PANASONIC CORP (JP) | 2018-03-14 | — | — | EP | disclosed |
| EP-2504338-B1 | PYRIDINE-PYRIDINONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2015-03-18 | — | — | EP | disclosed |
| US-8729532-B2 | Light-absorbing material and photoelectric conversion element | PANASONIC CORPORATION (JP) | 2014-05-20 | — | — | US | disclosed |
| US-8729532-B2 | Light-absorbing material and photoelectric conversion element | PANASONIC CORPORATION (JP) | 2014-05-20 | — | — | US | disclosed |
| US-8623893-B2 | Pyridino-pyridinone derivatives, preparation and therapeutic use thereof | SANOFI (FR) | 2014-01-07 | — | — | US | disclosed |
| US-20130005724-A1 | PYRIDINO-PYRIDINONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-01-03 | — | — | US | disclosed |
| EP-2524915-A1 | 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors | SANOFI (FR) | 2012-11-21 | — | — | EP | disclosed |
| EP-2504338-A1 | PYRIDINE-PYRIDINONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-10-03 | — | — | EP | disclosed |
| US-20120181516-A1 | LIGHT-ABSORBING MATERIAL AND PHOTOELECTRIC CONVERSION ELEMENT | PANASONIC ELECTRIC WORKS CO., LTD. (JP) | 2012-07-19 | — | — | US | disclosed |
| US-20120181516-A1 | LIGHT-ABSORBING MATERIAL AND PHOTOELECTRIC CONVERSION ELEMENT | PANASONIC ELECTRIC WORKS CO., LTD. (JP) | 2012-07-19 | — | — | US | disclosed |
| EP-2433989-A1 | LIGHT-ABSORBING MATERIAL AND PHOTOELECTRIC CONVERSION ELEMENT | Panasonic Corporation (JP) | 2012-03-28 | — | — | EP | disclosed |
| WO-2011061458-A1 | PYRIDINE-PYRIDINONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005724-A1 | PYRIDINO-PYRIDINONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | PDGFRB, FLT3, PDGFRA | CYP19A1 1294/4885ALDH1A1 847/4885EGLN3 1954/4885 |
| US-20120181516-A1 | LIGHT-ABSORBING MATERIAL AND PHOTOELECTRIC CONVERSION ELEMENT | PPOX, CRY1, CYBA | CYP19A1 192/4885ALDH1A1 110/4885EGLN3 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.